1. Home
  2. HFRO vs AGEN Comparison

HFRO vs AGEN Comparison

Compare HFRO & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Highland Opportunities and Income Fund of Beneficial Interest

HFRO

Highland Opportunities and Income Fund of Beneficial Interest

HOLD

Current Price

$6.04

Market Cap

406.7M

Sector

Finance

ML Signal

HOLD

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$6.31

Market Cap

335.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HFRO
AGEN
Founded
2000
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
406.7M
335.6M
IPO Year
2017
1999

Fundamental Metrics

Financial Performance
Metric
HFRO
AGEN
Price
$6.04
$6.31
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $26.33
AVG Volume (30 Days)
88.2K
★ 986.1K
Earning Date
01-01-0001
11-05-2026
Dividend Yield
★ 8.87%
N/A
EPS Growth
N/A
★ 100.00
EPS
N/A
★ 0.96
Revenue
N/A
★ $42,877,086.00
Revenue This Year
N/A
$9.64
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$6.75
Revenue Growth
N/A
★ 89.95
52 Week Low
$5.47
$2.71
52 Week High
$7.74
$10.19

Technical Indicators

Market Signals
Indicator
HFRO
AGEN
Relative Strength Index (RSI) 22.01 38.65
Support Level $5.47 $2.96
Resistance Level $6.36 $8.64
Average True Range (ATR) 0.15 0.46
MACD -0.03 -0.14
Stochastic Oscillator 4.05 13.25

Price Performance

Historical Comparison
HFRO
AGEN

About HFRO Highland Opportunities and Income Fund of Beneficial Interest

Highland Opportunities and Income Fund is a non-diversified, closed-end management investment company. Its investment objective is to Income Fund seeks growth of capital along with income. It focuses on making investments in real estate securities, including Reits, secured and unsecured fixed-rate loans and corporate bonds, mezzanine securities, structured products, convertible and preferred securities and equities (public and private), and floating rate securities.

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

Share on Social Networks: